633 results on '"Filleron, T."'
Search Results
2. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort
3. Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors
4. Evaluation of two modalities of perioperative treatment in the management of extremity and truncal soft tissue sarcomas: neoadjuvant concurrent chemoradiotherapy and sequential treatment
5. CO2.3 - Optimal treatment regimes for the net benefit of a treatment
6. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
7. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy
8. Goftte: A R package for assessing goodness-of-fit in proportional (sub) distributions hazards regression models
9. Caractéristiques et prise en charge de l’évolutivité cérébro-méningée des cancers bronchiques dans un contexte de mutation activatrice
10. Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package
11. Total body irradiation using Helical Tomotherapy®: Treatment technique, dosimetric results and initial clinical experience
12. P003 - Intérêt des modèles pour événements récurrents dans l'analyse des toxicités associées aux nouvelles thérapeutiques en oncologie
13. 217P Incidence and outcome of brain and/or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort
14. How to report toxicity associated with targeted therapies?
15. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
16. Pseudoprogression versus true progression in patients with glioblastoma: A multiapproach analysis
17. Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R
18. Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study
19. L’élévation du TNF plasmatique est associée à l’échec des immunothérapies du mélanome : résultats de l’essai clinique MELAN-F alpha
20. Comparaison des réponses thérapeutiques durables dans le mélanome métastatique, par modèle de guérison flexible paramétrique : une étude de vie réelle sur une cohorte de 273 patients
21. Comment effectuer des comparaisons indirectes ajustées par appariement (MAIC) avec imputations multiples des données manquantes et dans un contexte de faibles échantillons ? Une méthodologie illustrée dans le cancer du poumon à partir d'essais cliniques agrégés et de la cohorte nationale ESME-AMLC
22. Triple association de l’ipilimumab + nivolumab + anti-TNF pour le traitement du mélanome : analyse finale de TICIMEL, un essai prospectif de phase IB
23. 260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial
24. 1122P An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients
25. 853P TNF plasma levels in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study
26. 846P Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial
27. Dermatofibrosarcoma protuberans: Margins reduction using slow-Mohs micrographic surgery. Experience with 35 patients
28. Place de la radiothérapie dans le traitement conservateur des sarcomes en territoire irradié
29. Carcinome canalaire in situ avec micro-invasion : spécificités anatomopathologiques et implications cliniques
30. Role of radiation therapy in the conservative management of sarcoma within an irradiated field
31. Body composition and anti-neoplastic treatment in adult and older subjects - A systematic review
32. Surgical Complexity Impact on Survival After Complete Cytoreductive Surgery for Advanced Ovarian Cancer
33. Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer
34. Accuracy of intraoperative pathological examination of SLN in cervical cancer
35. Récidives pelviennes de cancers du rectum à composante extraluminale: Évaluation des rapports pelviens par l’imagerie préopératoire, impact sur l’étendue de l’exentération pelvienne et concordance radiohistologique
36. The frontal branch of the facial nerve: can we define a safety zone?
37. Stratégie d’évaluation de la valeur pronostique de biomarqueurs continus. Illustration avec la charge mutationnelle dans le sang chez les patients traités par immunothérapie
38. Approche statistique pour déterminer le délai minimal pour définir la guérison dans le cadre d'un traitement par immunothérapie : Application à l’étude CHECKMATE-067
39. Laparoscopic pelvic exenteration for gynaecological malignancy: Is there any advantage?
40. Évaluation en vie réelle du pembrolizumab en monothérapie dans le traitement du CBNPC métastatique PD-L1-positif (TPS ≥ 50 %) en France
41. Évaluation en vie réelle du pembrolizumab en monothérapie dans le CBNPC avancé PD-L1 positif (TPS ≥ 1 %) précédemment traité, en France
42. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
43. 1760MO Impact of immune checkpoint blockade therapy according to CD274 copy number alterations: A retrospective study in the ProfiLER cohort
44. 552P Reasons of screening failure during the 28-day screening period in patients identified for inclusion in phase I trials and their outcome
45. 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer
46. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
47. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
48. OC-0333 Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial
49. Évaluation de différentes stratégies d’analyse pour préserver la puissance dans les essais randomisés en immuno-oncologie
50. Exploratory analyses of surrogate endpoints in metastatic non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.